Patents by Inventor Lars C. Petersen
Lars C. Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10717784Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.Type: GrantFiled: January 9, 2018Date of Patent: July 21, 2020Assignee: NOVO NORDISK A/SInventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
-
Publication number: 20180208675Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.Type: ApplicationFiled: January 9, 2018Publication date: July 26, 2018Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
-
Patent number: 9896513Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.Type: GrantFiled: March 14, 2014Date of Patent: February 20, 2018Assignee: Novo Nordisk A/SInventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
-
Publication number: 20160032012Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen
-
Patent number: 6183743Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.Type: GrantFiled: August 20, 1999Date of Patent: February 6, 2001Assignees: ZymoGenetics, Inc., Novo Nordisk A/SInventors: Charles E. Hart, Lars C. Petersen, Ulla Hedner, Mirella E. Rasmussen
-
Patent number: 5997864Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.Type: GrantFiled: June 6, 1997Date of Patent: December 7, 1999Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.Inventors: Charles E. Hart, Lars C. Petersen, Ulla Hedner, Mirella E. Rasmussen
-
Patent number: 5629176Abstract: A variant of the C-terminal Kunitz-type protease inhibitor domain of the .alpha.3 chain of human type VI collagen, the variant comprising the following amino acid sequence X.sup.1 X.sup.16 Asp Ile Cys Lys Leu Pro Lys Asp X.sup.2 Gly X.sup.3 Cys X.sup.4 X.sup.5 X.sup.6 X.sup.7 X.sup.8 X.sup.9 Trp Tyr Tyr Asp Pro Asn Thr Lys Ser Cys Ala Arg Phe X.sup.10 Tyr Gly Gly Cys X.sup.11 X.sup.12 X.sup.13 Glu Asn Lys Phe X.sup.14 Ser Gln Lys Glu Cys Glu Lys Val Cys Ala Pro X.sup.15 (SEQ ID NO. 1) wherein X.sup.1, X.sup.15, and X.sup.16 represents a naturally occurring amino acid residues except Cys and X.sup.2 -X.sup.14 each independently respresents a naturally occurring amino acid residue, with the proviso that at least one of the amino acid residues X.sup.1 -X.sup.16 is different from the corresponding amino acid residue of the native sequence. Alternatively, the N-terminal Asp may be preceded by H or 3-5 amino acid residues and the C-terminal Pro may be followed by OH or 3-5 amino acid residues.Type: GrantFiled: November 4, 1994Date of Patent: May 13, 1997Assignee: Novo Nordisk A/SInventors: S.o slashed.ren E. Bj.o slashed.rn, Kjeld Norris, Fanny Norris, Lars C. Petersen, Ole H. Olsen
-
Patent number: 5621074Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.Type: GrantFiled: May 18, 1995Date of Patent: April 15, 1997Assignee: Novo Nordisk A/SInventors: Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen
-
Patent number: 5618915Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.Type: GrantFiled: May 18, 1995Date of Patent: April 8, 1997Assignee: Novo NordiskInventors: Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen
-
Patent number: 5618696Abstract: The present invention relates to a human Kunitz-type protease inhibitor comprising the following amino acid sequenceAsp Leu Leu Pro Asn Val Cys Ala Phe Pro Met Glu Lys Gly Pro Cys Gln Thr Tyr Met Thr Arg Trp Phe Phe Asn Phe Glu Thr Gly Glu Cys Glu Leu Phe Ala Tyr Gly Gly Cys Gly Gly Asn Ser Asn Asn Phe Leu Arg Lys Glu Lys Cys Glu Lys Phe Cys Lys Phe Thr(SEQ ID NO:1)or a variant thereof with protease inhibitor properties.Type: GrantFiled: February 6, 1995Date of Patent: April 8, 1997Assignee: Novo Nordisk A/SInventors: Fanny Norris, Kjeld Norris, S.o slashed.ren E. Bj.o slashed.rn, Lars C. Petersen, Ole H. Olsen, Donald C. Foster, Cindy A. Sprecher
-
Patent number: 5591603Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.Type: GrantFiled: June 23, 1993Date of Patent: January 7, 1997Assignee: Novo Nordisk A/SInventors: Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen
-
Patent number: 5576294Abstract: Variant of human Kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI), the variant comprising the following amino acid sequence ##STR1## wherein Xaa at position 1 is H or a naturally occurring amino acid residue except Cys, each Xaa at positions 2-5 is independently a naturally occurring amino acid residue except Cys or is absent, each Xaa at positions 14, 16, 18, 19, 20, 21, 22, 23, 37, 42, 43, 44, and 49 independently a naturally occurring amino acid except Cys, each Xaa at positions 61, 62, 63, and 64 is independently a naturally occurring amino acid except Cys or is absent, and Xaa at position 65 is OH or a naturally occurring amino acid except Cys, with the proviso that at least one of the amino acid residues designated Xaa is different from the amino acid residue of the native sequence.Type: GrantFiled: October 12, 1994Date of Patent: November 19, 1996Assignee: Novo Nordisk A/SInventors: Fanny Norris, Kjeld Norris, S.o slashed.ren E. Bj.o slashed.rn, Lars C. Petersen, Ole H. Olsen
-
Patent number: 5373090Abstract: This invention relates to novel aprotinin analogues having a selected inhibition profile against serine proteases.Type: GrantFiled: November 19, 1990Date of Patent: December 13, 1994Assignee: Novo Nordisk A/SInventors: Kjeld Norris, Lars C. Petersen